Will Samsung BioLogics be delisted?
By Lee Kyung-min The Korea Exchange (KRX) will soon determine whether to refer a review on delisting of Samsung BioLogics to its subcommittee.This is the latest development of Samsung Group's scandal-ridden biopharmaceutical arm whose stocks remain suspended from transaction since Nov. 14 upon the ruling from the Securities and Futures Commission (SFC) under the Financial Services Commission that concluded the firm intentionally cooked accounting books in 2015. The KRX will determine no later than Dec. 5 whether the case requires an in-depth review by the Listing Maintenance Review (LMR) over three standards ― transparency, continuity and protection of interest of both the public and investors. If put forth, the commission will carry out a 20-day review to determine whether the firm should be delisted, have its stock trading resumed or be given a grace period until further review. If KRX decides against the referral, Samsung BioLogics shares will resume trading the following business day. The KRX has been looking into the issue since Nov. 14, and the decision will be made as schedule
